Skip to content

MDMA for PTSD: all studies

Page 4 of 21: studies 31 to 40 of 204, newest first. Back to the MDMA for PTSD overview

Research

Psychedelics as a Therapeutic Opportunity or Threat: A Narrative Review.

Cureus December 1, 2025 Paweł Liszka, Agata Ogórek, Klaudia M Olejnik-Chlewicka et al.

Classic psychedelics and related substances, such as 3,4-methylenedioxymethamphetamine (MDMA), have again become a focus of interest in psychiatry as potential therapeutic tools. The aim of this paper is to review current data on their mechanisms of action, clinical applications in the treatment of mood and anxiety disorders, addictions and post-traumatic stress disorder (PTSD), as well as to...

Self-compassion mediates treatment effects in MDMA-assisted therapy for posttraumatic stress disorder.

European Journal of Psychotraumatology December 1, 2025 Gabrielle Agin-Liebes, Richard J. Zeifman, Jennifer Mitchell 11 citations

Background: Posttraumatic stress disorder (PTSD) is a severe condition often complicated by co-occurring disorders, such as major depression, alcohol use disorder, and substance use disorders. A well-powered phase 3 randomized, placebo-controlled trial has shown that MDMA-assisted therapy (MDMA-AT) may be an effective treatment for severe PTSD. However, the psychological mechanisms driving the...

Comparative Efficacy of Psilocybin and MDMA in PTSD Treatment: A Systematic Review of Long-Term Outcomes

Berkeley Scientific Journal November 13, 2025 Presley Aspen

Highly stressful events can lead to post-traumatic stress disorder (PTSD)-a significant public health concern which existing treatments (e.g., psychotherapy and traditional medications) have shown marginal efficacy for.Psychedelics-alternatively called hallucinogens-are psychoactive substances that cause perception, mood, and cognitive changes.Because they are known for their impact on neuron...

MDMA-Assisted Psychotherapy for PTSD: A Systematic Review of Randomized Control Trials

Journal of Psychoactive Drugs November 5, 2025 B Brett, Christine Bynum 4 citations

Posttraumatic stress disorder (PTSD) is a serious and chronic mental health condition with limited effective treatment options. 3,4-methylenedioxymethamphethamine (MDMA)-assisted psychotherapy (MDMA-AT) has shown promise in phase 2 and phase 3 clinical trials, with many research participants reporting significant reductions in PTSD symptoms. However, the Federal Drug Administration (FDA)...

DOI: 10.1080/02791072.2025.2577308 (opens in new tab) MDMA Placebo Randomized controlled trial Posttraumatic stress +7

Evaluating the efficacy and safety of MDMA for the treatment of Post Traumatic Stress Disorder: a systematic review

UCC Student Medical Journal October 17, 2025 Megha Kodancha, Houssein Chahrour, Charles Carey et al.

Background: Posttraumatic stress disorder (PTSD) affects approximately 5-7% of the population, with conventional treatments often proving inadequate for some patients. Recent studies suggest that methylenedioxymethamphetamine (MDMA) combined with psychotherapy may offer a novel therapeutic approach. This systematic review evaluates the efficacy and safety of MDMA-assisted psychotherapy for the...

DOI: 10.33178/smj.2025.1.4 (opens in new tab) MDMA Traumatic stress Randomized controlled trial Clinical psychology +8

MDMA in Psychiatry: From PTSD to emerging indications, safety, and future directions

Psychedelics October 14, 2025 Mingming Zhao, Jianjun Yang, Kenji Hashimoto

MDMA, 3,4-methylenedioxymethamphetamine (“ecstasy,” “molly”), is a distinctive entactogen that reverses the serotonin (5-HT) transporter to increase synaptic 5-HT, while also engaging catecholaminergic and oxytocinergic pathways. In clinical trials, MDMA-assisted psychotherapy has yielded substantial improvements in treatment-resistant posttraumatic stress disorder (PTSD), although regulatory...

Questions and Concerns About MDMA-Assisted Therapy (MDMA-AT) in Veterans with PTSD Symptoms

Journal of Psychoactive Drugs October 10, 2025 Mitch Earleywine, Caitlin Holley, Henry A MacConnel et al.

MDMA-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) shows promise, but attitudes and beliefs about this treatment, especially in symptomatic veterans, remain poorly understood. We sought to explore relevant attitudes in veterans receiving healthcare from Veterans Affairs as a step toward designing relevant surveys or psychoeducation materials for future work. We employed a...

DOI: 10.1080/02791072.2025.2570938 (opens in new tab) Anxiety Psychoeducation Curiosity Narrative +11

MDMA-assisted Acceptance and Commitment Therapy for Posttraumatic Stress Disorder: Rationale for a New Approach

September 7, 2025 Mathew Herbert, Brian H. Blanco, Dimitri Perivoliotis et al. preprint

There is promise for 3,4-Methylenedioxymethamphetamine (MDMA)-assistedpsychotherapy as a highly effective and durable treatment for posttraumatic stress disorder(PTSD). However, the Food and Drug Administration rejected MDMA-assisted psychotherapy inits current form, expressing concerns about the lack of standardization and empirical basis ofpsychotherapy methods. This highlights the need to...

DOI: 10.31234/osf.io/7xyfq_v1 (opens in new tab) MDMA Standardization Posttraumatic stress Cognition +5

The Potential Economic and Public Health Impact of MDMA‐Assisted Group Therapy for PTSD in Ukraine

World Medical & Health Policy August 21, 2025 Elliot Marseille, Olga Chernoloz, Ю. Д. Шмидт 1 citation

ABSTRACT The war in Ukraine has led to widespread trauma, with 6.4 million people suffering from severe, chronic posttraumatic stress disorder (PTSD). This study evaluates the cost‐effectiveness and societal impact of implementing modified group MDMA‐assisted therapy (MAT), with supplemental individual therapy for PTSD treatment in Ukraine. Using a decision analysis model, we estimated clinical...

DOI: 10.1002/wmh3.70039 (opens in new tab) MDMA Group psychotherapy Public health Group periodic table +2

MDMA to Treat PTSD in Adults

Psychopharmacology Bulletin August 12, 2025 Dustin Latimer, Michael D. Stocker, Kia Sayers et al. 10 citations

Post-traumatic stress disorder (PTSD) has become one of the most common psychiatric diagnosis in the United States specifically within the veteran population. The current treatment options for this debilitating diagnosis include trauma-focused psychotherapies along with selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI). 1 MDMA has recently...